Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 19/20 | 0.64 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.47 |
| ▸ | ELOC | Q15369 | 2/20 | 0.46 |
| ▸ | ELOB | Q15370 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25306142 | 1.00 | VHL (0.64) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25263224 | 1.00 | VHL (0.64) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25306357 | 1.00 | VHL (0.64) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25307073 | 1.00 | VHL (0.64) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25262411 | 0.92 | VHL (0.67) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25306156 | 0.92 | VHL (0.67) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25309152 | 0.90 | VHL (0.59) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25311891 | 0.90 | VHL (0.59) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25311894 | 0.90 | VHL (0.59) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL25309154 | 0.90 | VHL (0.59) | VHLSMARCA2SMARCA4ELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | VHL 3/4885SMARCA2 1054/4885SMARCA4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.